<i id='39C857C86D'><strike id='39C857C86D'><tt id='39C857C86D'><pre id='39C857C86D'></pre></tt></strike></i>
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri
read more
PauloAmorim/VWPicsviaAPImagesLONDON—EuropeanregulatorsonFridayrecommendedtheapprovalofPfizer’sRSVvac
read more
AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger
read moreAnimportbanofcertainAppleWatchesofficiallygoesintoeffectonTuesday.JustinSullivan/GettyImagesAnimport
